Drug development

#Cancer research #Drug delivery #Drug development #HPV #Immunology / Virology & Vaccines

HPV vaccine proven to dramatically reduce cervical cancer 

After decades of research, the UK implemented a human papillomavirus (HPV) vaccine programme for teenage girls in 2008. Now, for the first time, a study has shown that the UK HPV vaccine programme works and will save lives, according to research funded by Cancer Research UK.  The vaccine was shown to… Read More

#News

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals has harnessed the power of clinical… Read More

#Business & Investment #Exclusive Content #News

#Biologics #Drug development #Flow Cytometry #Immunogenicity #Therapeutics

Cellular assays to bridge the gap in immunogenicity prediction 

Listen to this article on the DDW Podcast: Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.  Biologic drugs as therapy have improved the treatment of many diseases, but their success is often tempered by antidrug antibodies (ADAs),… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Drug design #Drug development #Immunology / Virology & Vaccines #mRNA #RNA #Synthetic biology

RNA: a coming-of-age technology for viral vaccines 

Listen to this article on the DDW Podcast: Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.  Vaccines are one of the most effective healthcare interventions for reducing… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

#CRO #Data #Drug development

CatSci partners with Cambridge Crystallographic Data Centre 

Medicine developer CatSci has collaborated with the Cambridge Crystallographic Data Centre (CCDC). CatSci’s experimental expertise in material science combined with CCDC’s informatics tools will offer an integrated solution to customers, adding strategic value from molecule to medicine.  CCDC’s informatics-based services apply big data learnings from over one million published crystal structures to better… Read More

#News

#Cancer #Clinical trials #Drug development #Drug therapy

Experimental immunotherapy cancer treatment enters Phase II 

Australian clinical-stage drug development company Noxopharm has announced its DARRT-2 Phase II clinical trial has begun with patient enrollment in the US. It is said to have the potential to revolutionise cancer treatment by achieving cancer reduction without many of the unwanted side effects, cost limitations, and logistical challenges… Read More

#News

#Biotechnology #Drug development #Inflammatory Bowel Disease #Precision medicine

The start-up changing the game for IBD 

Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut health and IBD in… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone #Trends & Analysis

#Bioproduction #Drug delivery #Drug development

How can the bioprocess industry respond to cost and maintain quality? 

Listen to this article on the DDW Podcast: Grant Cameron, Director at Clydeworth Consulting, examines the benefits of process intensification and highlights the steps which will improve process productivity, reduce environmental impact and decrease the cost of therapy manufacture while maintaining product quality.  The move to continuous bioprocessing has been a major… Read More

#Business & Investment #Exclusive Content #Opinion

#Drug development #Drug discovery #Pharmaceuticals

Doloromics appoints President and Chief R&D Officer

Doloromics has appointed Dr. Chris Flores as their new President and Chief Research and Development Officer. In this role, Dr. Flores will be responsible for leading the Doloromics portfolio of drug discovery and development programmes, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators… Read More

#News

#Antibodies #Collaboration #Drug development #Drug discovery #Monoclonal antibodies

Nautilus and Abcam partner to accelerate proteome exploration  

Nautilus Biotechnology and Abcam have announced a strategic development and supply partnership to leverage Abcam’s recombinant monoclonal antibody development technologies and expertise to enhance Nautilus’ reagent research and development.   The partnership will initially focus on the collaborative development of affinity binding reagents for use on the… Read More

#News #Trending News

#Drug development #Neuroscience #Therapeutics

Appointment seeks to boost brain disorder therapy development 

Inscopix, a brain mapping platform, appointed David Gray as Chief Scientific Officer (CSO) in a new position to discover and develop more effective therapies for brain disorders.  Inscopix provides brain research tools to basic and translational researchers in academia as well as biotech and pharma companies in neuroscience. Read More

#News

#CAR-T #Cell and gene therapy #Collaboration #Drug development #Drug discovery

Sitting down with… Julian Cole, Cell & Gene Collective 

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis.  LR: What was… Read More

#Editor's Choice #Exclusive Content #News #Opinion

Handshake
#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

BioNet and BIA Separations collaborate to develop mRNA vaccines 

BioNet and BIA Separations, now part of Sartorius, have developed an optimised mRNA manufacturing process.   BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimisation and upscale of a high-yield… Read More

#News

#Drug development #Funding #Health #Healthcare #Public health

UK budget plans: healthcare industry reaction 

In the Autumn 2021 budget delivered by UK Chancellor of the Exchequer, Rishi Sunak, on 27 October, the Government announced a range of measures designed to benefit UK science, business, and technology. This, at a time where the UK’s health service will need to tackle backlogs through the Winter… Read More

#News #Trending News

#Biopharmaceuticals #Drug delivery #Drug development

Abcam acquires BioVision and expands kit 

Abcam has completed a $340m strategic acquisition of BioVision and doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam’s growth in the US, which the company says will enable it to support the research and biopharma… Read More

#News

#Drug development #Drug discovery #Funding #Therapeutics

Researchers awarded $12 million for personalised asthma therapies

A group of researchers led by Indiana University School of Medicine’s Benjamin Gaston has been awarded a research programme project grant from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalised… Read More

#News